Albert Bourla

Planning for the annual Association for Value-Based Cancer Care (AVBCC) Educational Summit & Program requires the insight of leaders from across the oncology ecosystem. We would like to extend our gratitude to the following members of our AVBCC 2024 Co-Chair Committee for the time, energy, and talent they've devoted to helping us ensure we once again deliver a tremendous event for our guests: Cheryl Ann Allen, MBA, BS Pharm, Founding Partner, Curatio Scientia Advisors Sibel Blau, MD, President & CEO, QCCA, LLC, Medical Director, Northwest Medical Specialties, PLLC Mark Chassay, MD, MEd, MBA, Chief Medical Officer, Blue Cross and Blue Shield of Texas Basit Chaudhry, MD, PhD, Founder, Tuple Health Nancy Daly, MS, MPH, CEO, Conquer Cancer Ranjani Durham, Senior Vice President and Head, US Market Access, BMS Doug Flora, MD, LSSBB, FACCC, Executive Medical Director, Oncology Services, St. Elizabeth Healthcare John Fox, MD, MHA, Senior Medical Director of the Americas, Market Access, Illumina Marianne Gandee, VP, Patient Solutions & Alliances, North America Pfizer Oncology Stephen Grubbs, MD, FASCO, VP, Care Delivery, American Society of Clinical Oncology Beth Hamilton, MBA, VP, Global Oncology Market, Access and Pricing, AstraZeneca Lisa Harrison, RPh, President and General Manager, Oncology Supply, Cencora David Johnson, MD, MPH, Clinical Operating Partner, Rubicon Founders Stan Kachnowski, PhD, MPA, Director, Digital Health Program, Columbia Business School Ira Klein, MD, MBA, FACP, VP, Medical Affairs, Payer Relations, Tempus Labs, Inc. Michael Kolodziej, MD, Chief Medical Officer, Canopy Lavi Kwiatkowsky, CEO & Founder, Canopy Lucy Ruwitch Langer, MS, MD, National Medical Director, Oncology and Genomics, UnitedHealthcare Join Luh, MD, FACP, FACR, Radiation Oncologist, Providence Health William McGivney, PhD, Managing Partner, McGivney Global Advisors Kathy Oubre, MS, CEO, Pontchartrain Cancer Center Debra Patt, MD, PhD, MBA, Executive Vice President, Policy and Strategic Initiatives, Texas Oncology Alti Rahman, MHA, MBA, CSSBB, Chief Strategy and Innovation Officer, American Oncology Network Chevon Rariy, MD, Chief Health Officer, Oncology Care Partners Marc Samuels, Founder & CEO, ADVI Health Muna Tuna, US Market Pricing and Reimbursement Leader, Ernest & Young, LLP Tim Ward, Esq., President, Hercules Lalan Wilfong, MD, VP, Payer Relations and Practice Transformation, The US Oncology Network Burt Zweigenhaft, PhD, DLitt, Co-Founder AVBCC #ValueBasedCancerCare #HealthcareLeaders #OncologyCare #HealthcarePolicy #ValueBasedCare #AVBCC #OncologySummit #HealthcareConference #Cancer #Oncology

7

Manufacturers anticipating potential selection or therapeutic impact for 2027 #Medicare negotiations should begin preparations and align internal decision-making now. In a new #AvalereInsight, Milena Sullivan, Megan West (Olsen), Mike Ciarametaro, and J. Lance Grady detail how stakeholders can apply learnings from year 1 and begin thinking about year 2 negotiation today: https://lnkd.in/enQTvd_e #IRA #InflationReductionAct #drugpricing #healthpolicy

26

We call on all governments to prioritize testing, treatment and vaccination for hepatitis - Tedros Adhanom Ghebreyesus World Health Organization #Cancer #HealthServices #Hepatitis #Liver #OncoDaily #Oncology #Vaccination #WHO #WorldHepatitisDay

20

Get to know the current & future MAFLD/MASH agents! Rezdiffra from Madrigal Pharmaceuticals has transformed the metabolic dysfunction-associated steatohepatitis (MASH) treatment area with its approval earlier this year. Looking at the attached PDF, it seems like that first-mover advantage could last some time based on the latest clinical development status from the closest MAFLD/MASH pipeline competitors. However, what is less certain is whether use of the GIP/GLP-1 agents for other conditions like obesity and type 2 diabetes will ultimately reduce the potential opportunity for MAFLD/MASH therapies. It is possible that treatment of patients for diabetes and obesity (often precursors of MAFLD/MASH) could shrink the target MAFLD/MASH patient population in a few years. Stay tuned to see if any upcoming clinical updates change the timing of and opportunity for a second FDA-approval in MASH. #MAFLD #MASH #prescriptiondrugs #drugspipeline #healthcareinnovation #pharmaceuticals #medicalresearch #biotech #clinicaltrials #drugdevelopment

6

1 Comment

While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily

5

“Scripius worked with one of its clients, Select Health, to quickly transition 98% of their Humira prescriptions to one of the adalimumab biosimilars. We believe this was the fastest transition in the country. “ Samsung Bioepis, recently sat down with our Pharmacy Services AVP, Matt Mitchell, to pick his brain on biosimilars' strategy. Matt explains the financial calculus, the obstacles of communicating a change to diverse audiences, and what he has learned from Scripius’ most recent biosimilars move. Here's the Q&A - https://lnkd.in/gd7SABgA #PBM #PharmacyBenefits #Biosimilars

37

3 Comments

Nearly 1,200 Medicines in Development to Tackle Costly Chronic Diseases There is a growing shift from treating diseases to preventing them, according to Dr. Michael Ybarra, MD , chief medical officer of PhRMA. PhRMA’s latest Medicines in Development report highlights a significant trend in preventive medicine, which could improve patient outcomes and reduce healthcare costs related to chronic diseases. The report points to a pipeline of nearly 1,200 medicines in development, reflecting advancements such as oral PCSK9 inhibitors for cholesterol management and monoclonal antibodies for conditions like asthma. "This is just the tip of the iceberg," said Dr. Ybarra, emphasizing the potential these innovations hold. Among the medicines in development are 62 targeting heart disease, 99 for breast cancer (a record high), and 53 for depression. Ybarra also acknowledged the inherent challenges of drug development, noting that only one in 10 medicines typically make it to market. This underscores the importance of maintaining a robust regulatory environment that supports innovation. He added that current GLP-1s and GLP/GIP combination therapies, already used for treating diabetes and obesity, are also showing promise in preventing related complications, including heart attacks, strokes, and certain cancers, potentially improving long-term health outcomes. Read more at, https://lnkd.in/dYrZ25zG | Healthcare Finance News | Nathan Eddy | HIMSS #pharmanews #healthcare #pharmaceutical #business #chronicdiseases #drugs #discovery #research #thehealthcolossus

1

Some very impressive (and exciting) results with therapeutic interfering particles targeting HIV from Leor Weinberger's lab... Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates. Abstract Antiviral therapies with reduced frequencies of administration and high barriers to resistance remain a major goal. For HIV, theories have proposed that viral-deletion variants, which conditionally replicate with a basic reproductive ratio [R0] > 1 (termed “therapeutic interfering particles” or “TIPs”), could parasitize wild-type virus to constitute single-administration, escape-resistant antiviral therapies. We report the engineering of a TIP that, in rhesus macaques, reduces viremia of a highly pathogenic model of HIV by >3log10 following a single intravenous injection. Animal lifespan was significantly extended, TIPs conditionally replicated and were continually detected for >6 months, and sequencing data showed no evidence of viral escape. A single TIP injection also suppressed virus replication in humanized mice and cells from persons living with HIV. These data provide proof of concept for a potential new class of single-administration antiviral therapies.

23

5 Comments

BeiGene, a global oncology leader, and NewBridge Pharmaceuticals have jointly decided to conclude their successful partnership. This strategic decision aligns with BeiGene’s vision to expand its presence and directly manage operations in the MENA region. The collaboration, which began in 2020, focused on sales, distribution, and commercialization of BRUKINSA® (Zanubrutinib) in the MENA region, resulting in approvals by health authorities in multiple territories and currently marketed in several regions, with more approvals anticipated. The transition will occur on a country-by-country basis starting in June 2024 and completing by March 31, 2025, with BeiGene taking over all customer-facing activities from June 11, 2024. This strategic shift marks a significant milestone for BeiGene as it continues to expand its global presence, aiming to achieve groundbreaking advancements in the treatment of solid tumors and hematological cancers by 2025, reinforcing its dedication to providing cutting-edge cancer therapies worldwide. #Oncology #CancerCare #Healthcare #MedicalInnovation #Pharmaceuticals #GlobalExpansion #Partnership #MENARegion #Brukinsa #BeiGene #NewBridgePharma #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #PartnerIdentification #StrategySupport #ConferenceCoverage Detailed News: https://lnkd.in/d-UrURNN Follow our page for more industry updates: https://lnkd.in/de5zNWmK

22

2 Comments